Half Yearly Report and Accounts
Brisbane, Feb 22, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.
Highlights from the period include:
- Global animal health company, Zoetis Inc, exercising its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R).
- Establishing an experienced veterinary team focused on launching Detach(R) into the anti-diarrhoeal therapeutic pig market.
- Developing a proprietary dosing device for the optimal delivery of Detach(R) by pig farmers
- Presenting at the Australasian Pig Science Association (APSA) Conference - highlighting the comparable efficacy of Detach(R) to in-feed Zinc Oxide
- Increasing focus on human opportunities through the development of proprietary products for the management of diarrhoea associated with gastrointestinal disorders
To view the full report, please visit:
http://abnnewswire.net/lnk/155QR045
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
